share_log

T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

T2 Biosystems宣佈完成根據納斯達克規則在市場上定價的800萬美元私募配售
T2 Biosystems ·  05/17 12:00

LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $3.70 per share and are exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance.

馬薩諸塞州列剋星敦,2024年5月17日(GLOBE NEWSWIRE)——快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者T2 Biosystems, Inc.(納斯達克股票代碼:TTOO)今天宣佈,已完成先前宣佈的私募配售,購買和出售總計2,025,317股普通股(或代替其的預先籌資認股權證),A系列購買最多2,025,317股普通股的認股權證和以每股3.95美元的收購價購買最多2,025,317股普通股的短期B系列認股權證普通股(或以每份預先注資的認股權證代替)和根據納斯達克規則在市場上定價的附帶認股權證。A系列認股權證和短期B系列認股權證的行使價爲每股3.70美元,發行後可立即行使。A系列認股權證將自發行之日起五年半到期,短期B系列認股權證將在發行之日起十八個月後到期。

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

H.C. Wainwright & Co. 擔任本次發行的獨家配售代理。

The gross proceeds from the offering were approximately $8 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes, including sales and marketing, manufacturing and clinical development costs.

在扣除配售代理費和公司應付的其他發行費用之前,此次發行的總收益約爲800萬美元。公司打算將本次發行的淨收益用於營運資金和其他一般公司用途,包括銷售和營銷、製造和臨床開發成本。

The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement, the Company has agreed to file a resale registration statement covering the securities described above.

上述證券是根據經修訂的1933年《證券法》(“證券法”)第4(a)(2)條和/或根據該法頒佈的D條以私募方式發行的,與認股權證相關的普通股尚未根據《證券法》或適用的州證券法進行註冊。因此,除非根據有效的註冊聲明或《證券法》和此類適用的州證券法註冊要求的適用豁免,否則不得在美國發行或出售認股權證和普通股的標的股票。根據註冊權協議,公司已同意提交一份涵蓋上述證券的轉售註冊聲明。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

本新聞稿不構成出售要約或招攬購買這些證券的要約,也不得在根據任何此類州或其他司法管轄區的證券法進行註冊或資格認證之前,在任何州或其他司法管轄區出售這些證券是非法的。

About T2 Biosystems

關於 T2 生物系統

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme Panel.

T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者,致力於通過幫助臨床醫生比以往任何時候都更快地有效治療患者來改善患者護理和降低護理成本。T2 Biosystems的產品包括T2Dx儀器、T2Baceria Panel、T2Candida Panel、T2Resistance Panel和T2Biothreat Panel,由專有的T2磁共振(T2MR)技術提供支持。T2 Biosystems擁有一系列活躍的未來產品,包括美國T2抗藥小組、耳念珠菌測試和T2Lyme試劑盒。

Forward-Looking Statements

前瞻性陳述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the use of proceeds from the private placement; statements about the Company's ability to regain compliance with the listing requirements of the Nasdaq Capital market, as well as statements that include the words "expect," "may," "should," "anticipate," and similar statements of a future or forward-looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; (iv) market and other conditions or (v) the factors discussed under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述。本新聞稿中包含的所有與歷史事實無關的陳述均應被視爲前瞻性陳述,包括但不限於私募收益的使用;關於公司恢復遵守納斯達克資本市場上市要求的能力的陳述,以及包含 “期望”、“可能”、“應該”、“預期” 等字樣的陳述以及具有未來或前瞻性質的類似陳述。這些前瞻性陳述基於管理層當前的預期。這些陳述既不是承諾也不是保證,但涉及已知和未知的風險、不確定性和其他重要因素,這些因素可能導致實際結果、業績或成就與前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異,包括但不限於 (i) 無法 (a) 實現承諾、合同或產品的預期收益;(b) 成功執行戰略優先事項;(c) 將產品推向市場;(d) 擴展產品的使用或採用;(e)) 獲取客戶證詞;(f) 準確預測增長假設;(g) 實現預期收入;(h) 產生預期的運營支出水平;或 (i) 增加客戶設施中的高風險患者人數;(ii) 早期數據無法預測最終結果;(iii) 未能在預期的時間範圍內或根本沒有提交或獲得預期的 FDA 申請或許可;(iv) 市場和其他條件或 (v) 因素在項目 1A 下進行了討論。公司於2024年4月1日向美國證券交易委員會(SEC)提交的截至2023年12月31日年度的10-K表年度報告中的 “風險因素”,以及公司不時向美國證券交易委員會提交的其他文件,包括我們的10-Q表季度報告和8-K表最新報告。這些和其他重要因素可能導致實際業績與本新聞稿中前瞻性陳述所示的結果存在重大差異。任何此類前瞻性陳述均代表管理層截至本新聞稿發佈之日的估計。儘管除非法律要求,否則公司可能會選擇在未來的某個時候更新此類前瞻性陳述,但它不承擔任何更新此類前瞻性陳述的義務,即使隨後發生的事件導致其觀點發生變化。因此,任何人都不應假設公司隨着時間的推移保持沉默意味着實際事件如此類前瞻性陳述中所明示或暗示的那樣得到證實。不應將這些前瞻性陳述視爲本新聞稿發佈之日後任何日期的公司觀點。

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com

投資者聯繫人:
菲利普·特里普泰勒,吉爾馬丁集團
ir@T2Biosystems.com

Primary Logo

Source: T2 Biosystems, Inc.

來源:T2 Biosystems, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論